AIM: Informing a person of their individual risk of developing a disease in the future may be sufficient to provide the person with the impetus to adopt risk reducing behaviours. The aim of this study was to determine if a personalised 10-year cardiovascular disease (CVD) risk estimate can increase physical activity and other risk reduction behaviours in adults at high risk of CVD. METHODS: Pilot 2 × 2 factorial randomised controlled trial conducted in Oxfordshire, UK including 194 adults at increased CVD risk (10-year CVD risk ≥ 20%) recruited from four general practices. Main outcome measure at one month was physical activity measured by accelerometer. RESULTS:Median (IQR) age was 62.3 (54.9, 66.1) years, 67% were men and 19% had known diabetes. Mean (SD) total accelerometer counts per day was 297 × 10(-3) (110 × 10(-3) ) and activity of moderate or greater intensity was undertaken for 53 (22) minutes per day. In the 185 (95%) participants attending follow-up an increase in physical activity was not seen. There was a non-significant 0.5% (p = 0.56) greater increase in accelerometer counts in those receiving personalised CVD risk estimates. No significant within or between group changes were seen at one month in estimated 10-year CVD risk. A net 7% decrease in mean LDL cholesterol (p = 0.004) was seen in the intervention group despite similar increases in new prescriptions for lipid lowering therapies. CONCLUSION: In adults at increased risk of CVD provision of personalised 10-year CVD risk estimates did not appear to increase physical activity or estimated CVD risk over a one-month period.
RCT Entities:
AIM: Informing a person of their individual risk of developing a disease in the future may be sufficient to provide the person with the impetus to adopt risk reducing behaviours. The aim of this study was to determine if a personalised 10-year cardiovascular disease (CVD) risk estimate can increase physical activity and other risk reduction behaviours in adults at high risk of CVD. METHODS: Pilot 2 × 2 factorial randomised controlled trial conducted in Oxfordshire, UK including 194 adults at increased CVD risk (10-year CVD risk ≥ 20%) recruited from four general practices. Main outcome measure at one month was physical activity measured by accelerometer. RESULTS: Median (IQR) age was 62.3 (54.9, 66.1) years, 67% were men and 19% had known diabetes. Mean (SD) total accelerometer counts per day was 297 × 10(-3) (110 × 10(-3) ) and activity of moderate or greater intensity was undertaken for 53 (22) minutes per day. In the 185 (95%) participants attending follow-up an increase in physical activity was not seen. There was a non-significant 0.5% (p = 0.56) greater increase in accelerometer counts in those receiving personalised CVD risk estimates. No significant within or between group changes were seen at one month in estimated 10-year CVD risk. A net 7% decrease in mean LDL cholesterol (p = 0.004) was seen in the intervention group despite similar increases in new prescriptions for lipid lowering therapies. CONCLUSION: In adults at increased risk of CVD provision of personalised 10-year CVD risk estimates did not appear to increase physical activity or estimated CVD risk over a one-month period.
Authors: Stephanie L Fowler; William M P Klein; Linda Ball; Jaclyn McGuire; Graham A Colditz; Erika A Waters Journal: Med Decis Making Date: 2017-03-31 Impact factor: 2.583
Authors: Kunal N Karmali; Stephen D Persell; Pablo Perel; Donald M Lloyd-Jones; Mark A Berendsen; Mark D Huffman Journal: Cochrane Database Syst Rev Date: 2017-03-14
Authors: Tom Nolan; Charlotte Dack; Kingshuk Pal; Jamie Ross; Fiona A Stevenson; Richard Peacock; Mike Pearson; David Spiegelhalter; Michael Sweeting; Elizabeth Murray Journal: Br J Gen Pract Date: 2015-03 Impact factor: 5.386
Authors: Camille Lassale; Marc J Gunter; Dora Romaguera; Linda M Peelen; Yvonne T Van der Schouw; Joline W J Beulens; Heinz Freisling; David C Muller; Pietro Ferrari; Inge Huybrechts; Guy Fagherazzi; Marie-Christine Boutron-Ruault; Aurélie Affret; Kim Overvad; Christina C Dahm; Anja Olsen; Nina Roswall; Konstantinos K Tsilidis; Verena A Katzke; Tilman Kühn; Brian Buijsse; José-Ramón Quirós; Emilio Sánchez-Cantalejo; Nerea Etxezarreta; José María Huerta; Aurelio Barricarte; Catalina Bonet; Kay-Tee Khaw; Timothy J Key; Antonia Trichopoulou; Christina Bamia; Pagona Lagiou; Domenico Palli; Claudia Agnoli; Rosario Tumino; Francesca Fasanelli; Salvatore Panico; H Bas Bueno-de-Mesquita; Jolanda M A Boer; Emily Sonestedt; Lena Maria Nilsson; Frida Renström; Elisabete Weiderpass; Guri Skeie; Eiliv Lund; Karel G M Moons; Elio Riboli; Ioanna Tzoulaki Journal: PLoS One Date: 2016-07-13 Impact factor: 3.240
Authors: Laura M C Welschen; Sandra D M Bot; Piet J Kostense; Jacqueline M Dekker; Daniëlle R M Timmermans; Trudy van der Weijden; Giel Nijpels Journal: Diabetes Care Date: 2012-08-24 Impact factor: 19.112
Authors: Juliet A Usher-Smith; Barbora Silarova; Ewoud Schuit; Karel G M Moons; Simon J Griffin Journal: BMJ Open Date: 2015-10-26 Impact factor: 2.692